Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone

• DOI: 10.1007/s11547-024-01931-7
• Publication Date: 2024-11-20T06:21:38Z
• Authors: Matthew S. Robertson; Yating Wang; SuChun Cheng; Hyesun Park; Shahar Glomski; Lauren C. Harshman; Amanda Pace; Jacqueline Kilar; Meredith Flynn; Lauren Gilbert; Atish D. Choudhury; Heather Jacene